Synaffix rustles up another ADC deal, allying with Emergence in $360M biobuck pact

Synaffix has landed another antibody-drug conjugate (ADC) partner. After inking deals with Genmab and MacroGenics this year alone, the Dutch biotech has landed a partnership with Emergence Therapeutics that could be worth $360 million.